June 9 at 11am – 12:30pm ET (sign up here)
Please join us for a review of key data presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. Bloomberg Intelligence analysts Marc Engelsgjerd, MD, and Sam Fazeli, PhD, and inThought Research analyst Matt Presby, PhD, will be joined by expert speakers Patrick Forde, MBBCh, and Ravi Vij, MD, for a discussion of ASCO presentations of interest, including emerging data from checkpoint inhibitors, cell therapies, and targeted small molecules.
Expert Speakers:
Patrick Forde, MBBCh
Director, Thoracic Oncology Clinical Research Program & Associate Professor of Oncology
Johns Hopkins School of Medicine
Dr. Forde treats patients with lung cancer, mesothelioma and other thoracic cancers. He completed training in internal medicine and oncology in Ireland prior to undertaking a further fellowship at Johns Hopkins. He is currently Director of the Thoracic Oncology Clinical Research Program at Johns Hopkins and Associate Member of the Bloomberg-Kimmel Institute for Cancer Immunotherapy. He has led development of a clinical-translational research program focused on the immuno-oncology of upper aerodigestive malignancies.
Ravi Vij, MD
Professor, Department of Medicine, Oncology Division
Washington University School of Medicine in St. Louis
Dr. Vij’s area of academic pursuit is the treatment of hematologic malignancies and hematopoietic stem cell transplantation. He serves on the Core Transplant, Myeloma and Leukemia Committees of the CALGB, the Myeloma Committee of the BMT Clinical Trials Network (CTN) and the Multiple Myeloma Cancer immunotherapy Guideline panel of the Society for Immunotherapy of Cancer. Dr. Vij has served as principal investigator on several national and institutional clinical trials looking at strategies to improve the outcome of patients with multiple myeloma, acute myeloid leukemia and myelodysplastic syndromes and played a role in the development drugs approved for Multiple Myeloma including Carfilzomib, Pomalidomide, Elotuzumab Selinexor and Isatuximab.
